Y. Jeffrey Wu

TL;DR: The chemoprotection route and timing of administration can be manipulated to maintain CDDP antitumor efficacy while protecting against toxicities.

TL;DR: Results show that NAC blocks both the death receptor and the mitochondrial apoptotic pathways induced by cisplatin, and provides an opportunity to manipulate route and timing to maintain cisPlatin antitumor efficacy while protecting against chemotherapy side effects.

TL;DR: In vivo ferumoxides/protamine sulfate-loaded leukocytes and splenocytes were detected by MRI after intracerebral injection and might provide useful information for monitoring leukocyte trafficking into the brain.

TL;DR: Intetumumab treatment either in vitro prior to cell infusion or intravenous before or after cell infusion prevented metastasis formation on MRI and decreased the number of metastases on histology, suggesting that breast cancer patients at risk of metastase might benefit from early intetumuab treatment.

TL;DR: Data support a Phase I/II clinical trial of delayed NAC to reduce ototoxicity in children with localized pediatric cancers and support a minimally nephrotoxic cisplatin therapy if delayed until 4 h after chemotherapy.